Personalized Medicine Plus Diagnostics Equals Profits for Investors
Linkedin

Personalized Medicine Plus Diagnostics Equals Profits for Investors

Stockholm : Sweden | Jul 20, 2012 at 2:09 PM PDT
Source: The Motley Fool
XX XX
Views: Pending
 
A recent advance in personalized medicine happened when the U.S...Based on history, this should be a big boost for sales of Erbitux. AstraZeneca's lung cancer drug Iressa, launched in 2002, had little success because of its high failure rate. The okay for Therascreen is a milestone since the FDA... FULL ARTICLE AT The Motley Fool
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
 
Advertisement
 
Advertisement
 

More From Allvoices

 
Tap_logo_330_110_event
 


Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc 2008-2013. All rights reserved.